Multiple financial institutions have updated their research coverage on Candel Therapeutics, maintaining 'Buy' ratings but adjusting price targets to a range of $11 to $19 per share. This indicates continued analyst confidence in the company's prospects, albeit with some recalibration of valuation expectations.
On November 14, 2026, several prominent financial institutions, including Bank of America and Stifel, updated their research on Candel Therapeutics. While all firms maintained their 'Buy' ratings, a positive signal for the company, they did adjust their price targets, which now span a range of $11 to $19 per share. This suggests that while analysts remain optimistic about Candel's long-term potential, there may be some nuanced shifts in their short-to-medium term valuation models or market outlook. For traders, this could imply a period of moderate volatility as the market digests these new price targets, but the overall 'Buy' consensus provides a supportive backdrop for the stock. The key opportunity lies in identifying whether the new price targets reflect a more realistic valuation or if there's still upside potential based on the underlying business fundamentals.